AstraZeneca

Switch Market flag for country-specific data. Right-click for chart options. Use arrows to navigate symbols.

Scope of Things episode covers AI drug repurposing, new breast cancer treatment trial, Jill Pellegrino's career shift, publication bias in psychiatric drug studies, and expert insights on AI in clinical trials from SCOPE Europe 2024.

Cellectis reported a $108 million increase in cash reserves to $264 million, driven by a $140 million investment from AstraZeneca. The collaboration initiated three new R&D programs, including two allogeneic CAR T therapies and an in vivo gene therapy. Cellectis is deprioritizing the UCART123 program to focus on more promising assets and extend its cash runway to 2027. The company plans to present Phase I data in 2025 and is committed to open communication with stakeholders.

FDA approves Caris Life Sciences' MI Cancer Seek as companion diagnostic for multiple cancer drugs across six cancer types, including solid tumours, breast cancer, colorectal cancer, melanoma, non-small cell lung cancer, and endometrial carcinoma. The assay uses whole exome sequencing (WES) and whole transcriptome sequencing (WTS) for molecular profiling of solid tumours.

The 'Zollinger-Ellison Syndrome (Gastrinoma) - Global Clinical Trials Review, 2024' report by ResearchAndMarkets.com offers a comprehensive overview of clinical trials, including trial numbers, enrollment trends, and sponsor types, aiding in strategic decision-making and competitive advantage.

The 'Zollinger-Ellison Syndrome (Gastrinoma) - Global Clinical Trials Review, 2024' report, available on ResearchAndMarkets.com, offers insights into clinical trials for Zollinger-Ellison Syndrome, including trial numbers, enrollment trends, and sponsor details across regions and countries.

Ionis Pharmaceuticals reports Q3 2024 financial results, highlighting progress with WAINUA U.S. launch, olezarsen FDA action date in December 2024, and donidalorsen HAE PDUFA date in August 2025. The company is on track to achieve 2024 financial guidance and increased cash guidance to $2.2 billion. Key pipeline milestones include positive CHMP opinion for WAINUA in the UK, QALSODY approval in China, and ongoing pivotal development programs for olezarsen and donidalorsen.

Ionis Pharmaceuticals reports Q3 2024 financial results, highlighting successful U.S. launch of WAINUA, upcoming FDA action dates for olezarsen and donidalorsen, and reaffirmed 2024 P&L financial guidance with increased cash guidance to $2.2 billion.